Pipeline
DiObex currently has no approved products in the United States or elsewhere.
DIO-901 (very low dose glucagon), VLDG™ is in development in an extended release formulation for the prevention of insulin induced hypoglycemia. In patients with type 1 diabetes (T1DM), optimizing glycemic control via insulin intensification, has been shown to delay the onset and slow the progression of diabetic retinopathy, nephropathy, and neuropathy, but also carries the downside risk of increased hypoglycemia. DIO-901 is designed to delay or avert nocturnal hypoglycemia induced by insulin intensification. DIO-901 has received Fast Track status from the Food and Drug Administration.